Raymond J. De Hont, Chairman and Chief Executive Officer of Met-Pro Corporation (NYSE:MPR), announced recently that the Company's Global Pump Solutions business unit has received an order to supply in excess of three hundred (300) corrosion resistant fiberglass centrifugal pumps for a marine life park at a world class casino resort complex in the heart of Southeast Asia.
The combination of horizontal and vertical pumps will be shipped beginning December 2010, with all of the pumps scheduled to ship before the end of the first quarter of the Company's upcoming fiscal year, starting February 1, 2011. The value of this order is $3.7 million, which now represents the single largest order ever received for Fybroc® brand pumps.
The marine life park will be a multi-themed seawater and freshwater aquarium with interactive man and animal encounter attractions on a grand scale never seen before. A combination of horizontal end suction and vertical pumps will be utilized for seawater circulation and filtration, both of which are critical to proper management of the aquarium's life support systems.
PWRM, Power 3 Medical Products Inc., PWRM.OB has signed a definitive agreement recently to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Through these processes, Power3 has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, for which it is currently engaged in Phase II clinical trials.
These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
Power3 Medical Product's Website
Key Tronic Corporation (Nasdaq:KTCC), recently reported that it plans to report its results for the first quarter of fiscal 2011 after market close on October 26, 2010.
Key Tronic will host a conference call to discuss its financial results at 2:00 PM Pacific (5:00 PM Eastern) on October 26, 2010. A broadcast of the conference call will be available at www.keytronic.com under Investor Relations or by calling 877-941-8632 or +1 480-629-9820. A 48-hour replay will be available by calling 800-406-7325 or +1 303 590 3030 (Access Code: 4370245). A replay will also be available on the Company's Web site.
Key Tronic is a leading contract manufacturer offering value-added design and manufacturing services from its facilities in the United States, Mexico and China.
KeyCorp (NYSE:KEY) recently released third quarter net income from continuing operations attributable to Key common shareholders of $163 million, or $.19 per common share.
These results compare to a net loss from continuing operations attributable to Key common shareholders of $422 million, or $.50 per common share, for the third quarter of 2009.
The third quarter 2009 results were negatively impacted by a $733 million loan loss provision. Third quarter 2010 net income attributable to Key common shareholders was $178 million compared to a net loss attributable to Key common shareholders of $438 million for the same quarter one year ago.
Net income attributable to Key common shareholders for the nine-month period ended September 30, 2010 was $111 million compared to a net loss attributable to Key common shareholders of $1.364 billion for the same period one year ago.
Cleveland-based KeyCorp is one of the nation's largest bank-based financial services companies, with assets of approximately $94 billion at September 30, 2010.
Keynote® Systems (Nasdaq:KEYN), the global leader in Internet and mobile cloud monitoring, and Yankee Group, the leading source of insight and counsel for builders, operators and users of connectivity solutions, previously declared that the two companies partnered this year to produce Yankee Group's annual mobile Web site ranking, Best of the Anywhere Web 2010. The highly popular research report provides an in-depth quantitative and qualitative evaluation of leading mobile Web sites.
Keynote Systems is the global leader in solutions for continuously improving the Internet and mobile experience.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (PWRM.OB).